Search Results

Displaying Results 26-50 of 69 "'JNJ'"
Making a selection with these dropdown will cause content on this page to change. News search result will update as each option is selected.
ICOTYDE™ (icotrokinra) one-year results confirm lasting skin clearance and favorable safety profile in once‑daily pill for plaque psoriasis

Mar 28, 2026, 10:00 ET ICOTYDE™ (icotrokinra) one-year results confirm lasting skin clearance and favorable safety profile in once‑daily pill for plaque psoriasis

Clinicaltrials.gov. A Study of JNJ-77242113 for the Treatment of Participants With Moderate-to-severe Plaque Psoriasis. Identifier NCT06143878. https://clinicaltrials.gov/study/NCT06143878?term=jnj-77242113&rank=10. Accessed May 2025.8 Clinicaltrials.gov. A Study of JNJ-77242113 for the Treatment

More news about: Johnson & Johnson

Mar 25, 2026, 09:23 ET ROMTech, the Only Privately Owned MedTech Company Named to LexisNexis' Top 100 Global Innovators for 2026

the companies on the LexisNexis list have market capitalizations ranging from billions to trillions of dollars. Among them are Johnson & Johnson (JNJ), Intuitive Surgical (ISRG), Stryker (SYK), Alphabet (GOOG/GOOGL), Meta Platforms (META), Nvidia (NVDA), and Amazon (AMZN). ROMTech, a privately

More news about: ROMTech

Craig Tendler, M.D., JNJ's Former Global Head of Oncology Clinical Development, to Lead TuHURA Bioscience's VISTA Program in AML and other Blood Related Cancers

Mar 23, 2026, 07:45 ET Craig Tendler, M.D., JNJ's Former Global Head of Oncology Clinical Development, to Lead TuHURA Bioscience's VISTA Program in AML and other Blood Related Cancers

Clinical Development, Diagnostics, and Global Medical Affairs of Johnson & Johnson Innovative Medicine Research & Development. During his tenure at JNJ, Dr. Tendler and his team worked in collaboration with the FDA and the European Medicines Agency to secure the worldwide approvals of transformational

More news about: TuHURA Biosciences, Inc.

FDA approval of ICOTYDE™ (icotrokinra) ushers in new era for first-line systemic treatment of plaque psoriasis with a targeted oral peptide

Mar 18, 2026, 07:49 ET FDA approval of ICOTYDE™ (icotrokinra) ushers in new era for first-line systemic treatment of plaque psoriasis with a targeted oral peptide

2025.11 Clinicaltrials.gov. A Study of JNJ-77242113 for the Treatment of Participants With Moderate-to-Severe Plaque Psoriasis. Identifier NCT06143878. https://clinicaltrials.gov/study/NCT06143878?term=jnj-77242113&rank=10. Accessed May 2025.12 Clinicaltrials.gov. A Study of JNJ-77242113 for the Treatment

More news about: Johnson & Johnson

Johnson & Johnson Announces U.S. FDA Approval of TECVAYLI® plus DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma, Offering a Potential New Standard of Care as Early as Second Line

Mar 05, 2026, 15:55 ET Johnson & Johnson Announces U.S. FDA Approval of TECVAYLI® plus DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma, Offering a Potential New Standard of Care as Early as Second Line

type, free, personalized one-on-one support from a Care Navigator, and resources and community connections. Learn more at TECVAYLI.com or by calling 833-JNJ-wMe1 (833-565-9631).About MajesTEC-3MajesTEC-3 is an ongoing, Phase 3 randomized study evaluating the safety and efficacy

More news about: Johnson & Johnson

Anxiety Treatment Boom: GAD Therapies Poised for Multi-Billion Dollar Expansion

Mar 05, 2026, 09:30 ET Anxiety Treatment Boom: GAD Therapies Poised for Multi-Billion Dollar Expansion

include: Helus PharmaTM (NASDAQ: HELP) (Cboe CA: HELP), Acadia Healthcare Company, Inc. (NASDAQ: ACHC), Johnson & Johnson (NYSE: JNJ), BrainsWay Ltd. (NASDAQ: BWAY), Firefly Neuroscience, Inc. (NASDAQ: AIFF).

More news about: Market News Updates

/C O R R E C T I O N -- Johnson & Johnson/

Mar 03, 2026, 19:36 ET /C O R R E C T I O N -- Johnson & Johnson/

erythematosusSPRING HOUSE, Pa., March 3, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced that nipocalimaba was granted U.S. Food and Drug Administration (FDA) Fast Track designation as a potential treatment for

More news about: Johnson & Johnson

Chronic Kidney Disease Market Poised to Expand Significantly During Forecast Period (2025-2034) as Demand for Early Diagnosis and Novel Therapies Increases | DelveInsight

Mar 03, 2026, 17:31 ET Chronic Kidney Disease Market Poised to Expand Significantly During Forecast Period (2025-2034) as Demand for Early Diagnosis and Novel Therapies Increases | DelveInsight

REGN), AION Healthspan, Amgen (NASDAQ: AMGN), Maze Therapeutics (NASDAQ: MAZE), Eli Lilly (NYSE: LLY), Bayer AG (ETR: BAYN), Johnson and Johnson (NYSE: JNJ), Mitsubishi Tanabe Pharma Corporation, Lexicon Pharmaceuticals (NASDAQ: LXRX), Novo Nordisk (CPH: NOVO-B), and others

More news about: DelveInsight Business Research, LLP

Early study results from Johnson & Johnson show promising antitumor activity with combination of pasritamig and docetaxel in advanced prostate cancer

Feb 26, 2026, 14:30 ET Early study results from Johnson & Johnson show promising antitumor activity with combination of pasritamig and docetaxel in advanced prostate cancer

premedication for docetaxel, and hematopoietic growth factor support was permitted as needed.4About Pasritamig (JNJ-78278343)Pasritamig (JNJ-78278343) is an investigational T-cell-redirecting bispecific antibody (bsAb) targeting human kallikrein 2 (KLK2) on prostate cancer cells

More news about: Johnson & Johnson

Johnson & Johnson seeks FDA approval of IMAAVY® (nipocalimab-aahu) as the first-ever FDA-approved treatment for warm autoimmune hemolytic anemia (wAIHA)

Feb 24, 2026, 16:03 ET Johnson & Johnson seeks FDA approval of IMAAVY® (nipocalimab-aahu) as the first-ever FDA-approved treatment for warm autoimmune hemolytic anemia (wAIHA)

anemiaSPRING HOUSE, Pa., Feb. 24, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA), seeking approval

More news about: Johnson & Johnson

TREMFYA® (guselkumab) long-term data show sustained clinical and endoscopic remission in ulcerative colitis through 3 years

Feb 21, 2026, 08:00 ET TREMFYA® (guselkumab) long-term data show sustained clinical and endoscopic remission in ulcerative colitis through 3 years

(NCT06049017)ANTHEM-UC is a Phase 2b multicenter, randomized, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of icotrokinra (JNJ-77242113, JNJ-2113) in patients with moderately to severely active ulcerative colitis who had an inadequate response or intolerance to conventional therapy (e.g.,

More news about: Johnson & Johnson

RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Breakthrough Therapy Designation for patients with advanced head and neck cancer

Feb 18, 2026, 07:30 ET RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Breakthrough Therapy Designation for patients with advanced head and neck cancer

cancerRARITAN, N.J., Feb. 18, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for subcutaneous amivantamab and

More news about: Johnson & Johnson

FDA approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) as the only EGFR-targeted therapy that can be administered once a month

Feb 17, 2026, 08:00 ET FDA approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) as the only EGFR-targeted therapy that can be administered once a month

cancer1,3-6HORSHAM, Pa., Feb. 17, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced the U.S. Food and Drug Administration (FDA) has approved a new, simplified monthly dosing schedule* for RYBREVANT FASPRO™ (amivantamab

More news about: Johnson & Johnson

EGFR-NSCLC Market to Observe Stunning Growth at a CAGR of 9.6% During the Forecast Period (2025-2034) | DelveInsight

Feb 11, 2026, 17:31 ET EGFR-NSCLC Market to Observe Stunning Growth at a CAGR of 9.6% During the Forecast Period (2025-2034) | DelveInsight

4568), AstraZeneca (LON: AZN), Jiangsu Hansoh Pharmaceutical, Boehringer Ingelheim, Pfizer (NYSE: PFE), Johnson & Johnson Innovative Medicine (NYSE: JNJ), Yuhan Corporation (KRX: 000100), Eli Lilly and Company (NYSE: LLY), and others

More news about: DelveInsight Business Research, LLP

Novel Serotonergic Agonists Positioned to Capture Share of $150B+ Neuropsychiatric Market

Feb 10, 2026, 08:30 ET Novel Serotonergic Agonists Positioned to Capture Share of $150B+ Neuropsychiatric Market

effectively.  Active Companies in the biotech space include:  Helus PharmaTM (NASDAQ: HELP) (Cboe CA: HELP), Johnson & Johnson (NYSE: JNJ), AbbVie Inc. (NYSE: ABBV), Takeda Pharmaceutical Company Limited (NYSE: TAK) and AstraZeneca PLC (NYSE: AZN).

More news about: Market News Updates

Johnson & Johnson elevates leadership in depression with new data at 2026 American College of Neuropsychopharmacology Annual Meeting

Jan 13, 2026, 08:00 ET Johnson & Johnson elevates leadership in depression with new data at 2026 American College of Neuropsychopharmacology Annual Meeting

presentedTITUSVILLE, N.J., Jan. 13, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) announced today that 11 abstracts featuring new data on its robust portfolio and pipeline in neuropsychiatry will be presented at the 64th Annual Meeting

More news about: Johnson & Johnson

Psoriasis Market to Exhibit Growth at a CAGR of 1.7% During the Forecast Period (2025-2034), Owing to Continuous Innovation in Biologic Therapies and Approval of Oral Small Molecules | DelveInsight

Jan 07, 2026, 17:31 ET Psoriasis Market to Exhibit Growth at a CAGR of 1.7% During the Forecast Period (2025-2034), Owing to Continuous Innovation in Biologic Therapies and Approval of Oral Small Molecules | DelveInsight

significantly expanded market value. Additionally, the launch of emerging therapies such as zasocitinib (Takeda/Nimbus Therapeutics), icotrokinra (JNJ-77242113 [Johnson & Johnson Innovative Medicine and Protagonist Therapeutics]), piclidenoson (CF101 [Can-Fite BioPharma]), ESK-001 (Alumis), SFA-002

More news about: DelveInsight Business Research, LLP

Johnson & Johnson unveils new data showing nipocalimab is the first and only investigational FcRn blocker with potential to reduce systemic lupus erythematosus (SLE) activity in a Phase 2 study

Jan 06, 2026, 08:03 ET Johnson & Johnson unveils new data showing nipocalimab is the first and only investigational FcRn blocker with potential to reduce systemic lupus erythematosus (SLE) activity in a Phase 2 study

SLESPRING HOUSE, Pa., Jan. 6, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced positive topline results from the Phase 2b JASMINE (

More news about: Johnson & Johnson

Johnson & Johnson Receives FDA Approval for TRUFILL n‑BCA Liquid Embolic System for the Treatment of Symptomatic Chronic Subdural Hematoma

Dec 18, 2025, 08:00 ET Johnson & Johnson Receives FDA Approval for TRUFILL n‑BCA Liquid Embolic System for the Treatment of Symptomatic Chronic Subdural Hematoma

IRVINE, Calif., Dec. 18, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) – Today, Johnson & Johnson MedTech, a leader in neurovascular care, announced that the U.S. Food and Drug Administration (FDA) has approved an expanded

More news about: Johnson & Johnson MedTech

Dec 17, 2025, 18:49 ET U.S. FDA Approval of RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Enables the Simplest, Shortest Administration Time for a First-Line Combination Regimen when Combined with LAZCLUZE® (lazertinib)

HORSHAM, Pa., Dec. 17, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) announced today that the U.S. Food and Drug Administration (FDA) approved RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj), the first and

More news about: Johnson & Johnson

Alger Russell Innovation Index Updates for Fourth Quarter 2025

Dec 15, 2025, 16:18 ET Alger Russell Innovation Index Updates for Fourth Quarter 2025

Johnson & JohnsonJNJDeletion

More news about: Alger

Earlier use of CARVYKTI® demonstrated lasting treatment-free remissions at 2.5 years in patients with relapsed or refractory multiple myeloma

Dec 06, 2025, 09:30 ET Earlier use of CARVYKTI® demonstrated lasting treatment-free remissions at 2.5 years in patients with relapsed or refractory multiple myeloma

survivalORLANDO, Fla., Dec. 6, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) announced today updated results from the Phase 3 CARTITUDE-4 study supporting durable treatment-free remissions as early as second line treatment with CARVYKTI®

More news about: Johnson & Johnson

Johnson & Johnson Teams Up with Naomi Watts to Reveal Why an Eye Exam is the Ultimate Self-Care Move for Women Over 40

Dec 03, 2025, 08:00 ET Johnson & Johnson Teams Up with Naomi Watts to Reveal Why an Eye Exam is the Ultimate Self-Care Move for Women Over 40

JACKSONVILLE, Fla., Dec. 3, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) – Johnson & Johnson, a global leader in eye health, has partnered with Academy Award–nominated actress, producer, and entrepreneur, Naomi Watts,

More news about: Johnson & Johnson MedTech

New long-term data reinforces TREMFYA® (guselkumab) as the only IL-23 inhibitor proven to substantially inhibit structural joint damage in active psoriatic arthritis

Nov 17, 2025, 08:05 ET New long-term data reinforces TREMFYA® (guselkumab) as the only IL-23 inhibitor proven to substantially inhibit structural joint damage in active psoriatic arthritis

NEW YORK, Nov. 17, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced new data from the Phase 3b APEX study showing that TREMFYA® continued to reduce both signs and symptoms of active psoriatic

More news about: Johnson & Johnson

FDA approval of CAPLYTA® (lumateperone) has the potential to reset treatment expectations, offering hope for remission in adults with major depressive disorder

Nov 06, 2025, 07:30 ET FDA approval of CAPLYTA® (lumateperone) has the potential to reset treatment expectations, offering hope for remission in adults with major depressive disorder

TITUSVILLE, N.J., Nov. 6, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) announced today that the U.S. Food and Drug Administration (FDA) approved CAPLYTA® (lumateperone) as an adjunctive therapy with antidepressants

More news about: Johnson & Johnson

Making a selection with these dropdown will cause content on this page to change. News search result will update as each option is selected.